Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus.

IF 20.6 1区 医学 Q1 RHEUMATOLOGY
Panagiotis Garantziotis, Lorenzo Beretta, Julius Lindblom, Georgia-Savina Moysidou, Dionysis Nikolopoulos, Ricardo Grieshaber-Bouyer, Melanie Hagen, Christina Bergmann, Andreas Wirsching, Aline Bozec, Matthias Schneider, Guillermo Barturen, George Bertsias, Dimitrios T Boumpas, Marta E Alarcón-Riquelme, Andreas Mackensen, Georg Schett, Ioannis Parodis
{"title":"Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus.","authors":"Panagiotis Garantziotis, Lorenzo Beretta, Julius Lindblom, Georgia-Savina Moysidou, Dionysis Nikolopoulos, Ricardo Grieshaber-Bouyer, Melanie Hagen, Christina Bergmann, Andreas Wirsching, Aline Bozec, Matthias Schneider, Guillermo Barturen, George Bertsias, Dimitrios T Boumpas, Marta E Alarcón-Riquelme, Andreas Mackensen, Georg Schett, Ioannis Parodis","doi":"10.1016/j.ard.2025.06.2132","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Early trials of CD19-chimeric antigen receptor (CAR) T cell therapy in systemic lupus erythematosus (SLE) show promise, but the molecular mechanisms underlying its disease-modifying effects remain unclear. We aimed to compare biological profiles and alterations following CD19-CAR T cell versus standard pharmacotherapy in SLE.</p><p><strong>Methods: </strong>Pseudo-bulk gene expression derived from single-cell RNA sequencing of peripheral blood mononuclear cells from 7 SLE patients before and after CD19-CAR T cell therapy was compared with whole-blood transcriptome data from 30 SLE patients in remission on standard pharmacotherapy and 31 SLE patients before and 6 months after treatment with rituximab, belimumab, or cyclophosphamide. Pathway analysis was conducted using Functional Analysis of Individual Microarray Expression and gene set enrichment analysis.</p><p><strong>Results: </strong>CD19-CAR T cell-induced remission was characterised by marked suppression of complement activation, type I interferon, DNA damage response (DDR), and cell death pathways compared with remission following conventional pharmacotherapy, alongside an upregulation of lipid metabolism pathways. Compared with rituximab and belimumab, CD19-CAR T cell therapy induced greater downregulation of type I/II interferon, DDR, and chemokine pathways. Compared with cyclophosphamide, CD19-CAR T cell therapy induced greater suppression of interferon, mitochondrial, and mammalian target of rapamycin signalling pathways.</p><p><strong>Conclusions: </strong>CD19-CAR T cell therapy induces substantial suppression of key immunological pathways involved in SLE, including complement activation and type I interferon responses, accompanied by a metabolic reprogramming. Molecular profiles of remission after CD19-CAR T cell therapy differ from those induced by conventional SLE pharmacotherapy, suggesting more profound CD19-CAR T cell-induced biological alterations.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.6000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the Rheumatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ard.2025.06.2132","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Early trials of CD19-chimeric antigen receptor (CAR) T cell therapy in systemic lupus erythematosus (SLE) show promise, but the molecular mechanisms underlying its disease-modifying effects remain unclear. We aimed to compare biological profiles and alterations following CD19-CAR T cell versus standard pharmacotherapy in SLE.

Methods: Pseudo-bulk gene expression derived from single-cell RNA sequencing of peripheral blood mononuclear cells from 7 SLE patients before and after CD19-CAR T cell therapy was compared with whole-blood transcriptome data from 30 SLE patients in remission on standard pharmacotherapy and 31 SLE patients before and 6 months after treatment with rituximab, belimumab, or cyclophosphamide. Pathway analysis was conducted using Functional Analysis of Individual Microarray Expression and gene set enrichment analysis.

Results: CD19-CAR T cell-induced remission was characterised by marked suppression of complement activation, type I interferon, DNA damage response (DDR), and cell death pathways compared with remission following conventional pharmacotherapy, alongside an upregulation of lipid metabolism pathways. Compared with rituximab and belimumab, CD19-CAR T cell therapy induced greater downregulation of type I/II interferon, DDR, and chemokine pathways. Compared with cyclophosphamide, CD19-CAR T cell therapy induced greater suppression of interferon, mitochondrial, and mammalian target of rapamycin signalling pathways.

Conclusions: CD19-CAR T cell therapy induces substantial suppression of key immunological pathways involved in SLE, including complement activation and type I interferon responses, accompanied by a metabolic reprogramming. Molecular profiles of remission after CD19-CAR T cell therapy differ from those induced by conventional SLE pharmacotherapy, suggesting more profound CD19-CAR T cell-induced biological alterations.

与常规药物治疗相比,CD19-CAR - T细胞治疗对系统性红斑狼疮反应的差异分子特征
目的:cd19嵌合抗原受体(CAR) T细胞治疗系统性红斑狼疮(SLE)的早期试验显示出希望,但其疾病修饰作用的分子机制尚不清楚。我们的目的是比较CD19-CAR - T细胞与标准药物治疗后SLE患者的生物学特征和变化。方法:将7例SLE患者在CD19-CAR - T细胞治疗前后的外周血单个核细胞单细胞RNA测序获得的伪大体积基因表达与30例标准药物治疗缓解期SLE患者和31例接受利图昔单抗、贝利姆单抗或环磷酰胺治疗前后6个月的全血转录组数据进行比较。通过个体微阵列表达功能分析和基因集富集分析进行通路分析。结果:与常规药物治疗后的缓解相比,CD19-CAR - T细胞诱导的缓解的特征是补体激活、I型干扰素、DNA损伤反应(DDR)和细胞死亡途径的显著抑制,同时脂质代谢途径上调。与利妥昔单抗和贝利单抗相比,CD19-CAR - T细胞治疗诱导I/II型干扰素、DDR和趋化因子途径的更大下调。与环磷酰胺相比,CD19-CAR - T细胞治疗诱导干扰素、线粒体和哺乳动物雷帕霉素信号通路靶点更大的抑制。结论:CD19-CAR - T细胞治疗可诱导SLE相关关键免疫通路的实质性抑制,包括补体激活和I型干扰素应答,并伴有代谢重编程。CD19-CAR - T细胞治疗后缓解的分子特征与传统SLE药物治疗诱导的不同,表明CD19-CAR - T细胞诱导的生物学改变更深刻。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases 医学-风湿病学
CiteScore
35.00
自引率
9.90%
发文量
3728
审稿时长
1.4 months
期刊介绍: Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信